EU High Court Clarifies Generics Question In J&J Case
By Jacqueline Bell ( June 18, 2009, 12:00 AM EDT) -- Europe's highest court has ruled that drugmaker Generics UK Ltd. should not be permitted to market a generic version of Alzheimer's disease treatment Reminyl — a victory for Johnson & Johnson and Shire PLC that settles a key question over drug product exclusivity in the European Union....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.